ClinicalTrials.gg
RecruitingNCT07226193Updated Sep 17, 2026

Detecting Peripheral Artery Disease With the Pulse

An interventional study of Segmental pulse arrival time assessment in Peripheral Artery Disease (PAD), sponsored by University of Nebraska. Recruiting at 1 site in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by University of Nebraska · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

1) The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD), and to investigate the impacts of local skin heating and foot elevation. The secondary purpose will be to investigate the impacts of age on segmental PAT. The subject population will include any adults 19 years of age or older with or without PAD. Exclusion criteria include having an aortic aneurysm with or without previous intervention, previous revascularization surgeries of the arteries in the legs/aorta, walking impairments independent of PAD, gangrene or ulcers of the toes/feet, and currently pregnant or breastfeeding. 3) All aims of the present study will be completed with a single laboratory visit. Descriptive measurements will include height, weight, age, sex, body fat percentage, and self-reported medication and health history. Subjects will lie in the supine position for 20-min. After rest, either the ankle-brachial index (ABI) or PAT will be assessed. After 10-min of further rest, the other measurement will be performed. ABIs will be assessed according to current guidelines: blood pressures will be assessed in the dorsal pedis and tibialis posterior arteries of both legs and the brachial arteries of both arms using a blood pressure cuff and Doppler ultrasound. PAT will be simultaneously assessed in both arms and legs using an investigational device with a 3-lead electrocardiogram sensor and four photoplethysmography (PPG) sensors. A PPG sensor will be applied to a finger on each hand and both big toes. Signals will be collected for 15-min with finger and toe sensor temperatures at 30 C. Toe sensor temperature will then be elevated to 45 C for 15-min. Finally, toe sensor temperature will remain at 45 C, and the feet will be elevated 8-in with a soft cushion for 15-min. Blood pressure in the arm and legs will be assessed at the end of each stage. Thermal images of the fingers and toes will be assessed before using the investigational device and after each stage. Subjects will then participate in a 6-min walking test (6MWT) to objectively establish walking capacity. The 6MWT will be performed in accordance with current guidelines. Segmental PATs will be compared with ABI and 6-min walking time to determine if segmental PATs can predict lower-extremity PAD (ABI) and the associated walking impairment (6MWT). This study is expected to last \~2.5hrs. 4) There will be no follow-up.

Read the detailed description

Specific Aim 1: Determine if segmental pulse arrival times can predict lower-extremity peripheral artery disease assessed with ankle-brachial index and the 6-min walking test.

Specific Aim 2: Determine if local skin heating of the toes and foot elevation improves the prediction of peripheral artery disease using segmental pulse arrival times.

Specific Aim 3: Determine the effects of age on segmental pulse arrival times.

After the process of informed consent, descriptive measurements will be assessed. Descriptive measures include height, weight, body composition, age, and sex. Height and weight will be assessed with a standard stadiometer and scale, respectively. Body composition will be assessed non-invasively with bio-electric impedance analysis (Omron HBF-306C Handheld Scanner, OMRON Healthcare, Kyoto, Japan). Bioelectric impedance devices send a small electric current through the body and estimates body fat percentage based on the impedance to electrical flow through the body segments. Our bio-electric impedance device creates a circuit between the hands and feet of the subject to estimate body fat percentage. The electric current used in bioelectric impedance devices is very small and cannot be felt by the participant. Subjects will also self-report their medication and health history.

After the assessment of descriptive measurements, subjects will rest in the supine position for 20-min. After 20-min of rest, the subjects will have either ankle-brachial index (ABI) or segmental pulse arrival times (PATs) assessed. After a 10-min period of rest, the other measurement will be assessed (either ABI or PAT). The order of ABI and PAT will be randomized, and all subjects will have ABI and PAT assessed.

1a) Assessment of PAT with the Investigational Device: The subjects will be instrumented with an investigational device comprised of an array of four photoplethysmography (PPG) sensors and one 3-lead electrocardiogram (ECG) sensor. Electrocardiogram is a non-invasive technique that is used to monitor the electrical dipoles generated by membrane potentials within the myocardium and electrical conduction systems of the heart. PPG is a non-invasive technique to assess hemoglobin content within the microcirculation of the skin. Our PPG sensors are applied superficially on the skin and shines continuous-intensity green light into the skin (580 nm). The green light is absorbed by hemoglobin. Therefore, by the modified Beer-Lambert principle, the amount of light reflected back to the PPG unit gives an index of hemoglobin content within the microvasculature. The PPG and ECG sensors are integrated into a microcontroller (small computer), which reads the voltages of the sensors and displays the data in real time in a custom computer software. Each PPG sensor will have a skin-safe double-sided adhesive attached to the sensor housing. A PPG sensor will be adhered to a finger on the palmar side of both hands. A PPG sensor will be adhered to the plantar aspect of both big toes. Altogether, there will be one PPG sensor per hand and one PPG sensor per foot. The ECG sensor will be applied to form limb leads: one electrode per wrist on the ventral aspect of the forearm and one electrode on a hair-free portion of the left leg. If an adequate ECG signal is not obtained using limb leads, then chest leads will be utilized. In this configuration, electrodes will be placed inferior to the left and right clavicle, and medial to the shoulders, and one electrode will be placed on the left lateral aspect of the ribcage near the apex of the heart. Once all sensors have been placed, the subject will rest in the supine position. Next, the temperature of the sensor housings attached to the fingers and toes will be warmed to 30 C, which is thermoneutral with skin temperature, and subjects will rest for 15-min. Blood pressure will then be assessed in the arm and legs with a standard automatic blood pressure device. After 15-min of signal collection, the toe sensor housings will be heated to 45 C to warm up the skin of the toes, and the finger sensor housings will remain warmed at 30 C for an additional 15-min. Blood pressure will then be assessed in the arm and legs with a standard automatic blood pressure device. Next, the lower legs will be elevated 8-in with a soft cushion. The toe sensors will remain heated at 45 C, and the finger sensors will remain at 30 C. Signals will be collected continuously for an additional 15-min. Finally, blood pressure will then be assessed in the arm and legs with a standard automatic blood pressure device. For all conditions, PAT will be calculated for each arm and each leg as the difference in time between the R-wave appearing in the ECG signal and the pulse wave appearing in the distal PPG signals. All four PAT values will be used to develop a composite score to estimate the presence of lower-extremity PAD. Leg asymmetry will be assessed with the ratio of PATs from left and right legs. Atherosclerotic plaque-mediated pulse wave slowing will be assessed as the ratio of PATs in the arms compared to the legs. The product of these ratios forms the composite score to detect lower-extremity PAD, which is sensitive to both 1) asymmetry in PATs in the legs (may indicate unilateral lower-extremity PAD) and 2) longer PATs in the legs compared to the arms (may indicate the presence of lower-extremity PAD).

1b) Thermal Imaging:A thermal imaging camera (FLIR T540) will be used to take thermal images of the skin where the PPG sensors will be/were applied. Thermal images will be taken 1) prior to all sensors being applied, 2) after warming the finger and toe sensors to 30 C, 3) after warming the finger sensors to 30 C and the toe sensors to 45 C without leg elevation, and 4) after warming the finger sensors to 30 C and the toe sensors to 45 C with leg elevation. The purpose of using the thermal camera is to document the local skin temperature before and after using the investigational device at each setting. The thermal camera will automatically select the warmest region of the image and document the temperature. Of note, the thermal imaging camera will be zoomed in on the fingers and toes where the PPG sensors were located, and no identifiable body parts (e.g., face) or clusters of body parts (e.g., zoomed out images) will be included in the thermal images. Therefore, the risk of identifying subjects with the thermal images will be minimized.

2) Assessment of ABI: ABI will be assessed according to current guidelines established by the American Heart Association and the American College of Cardiology. Blood pressures will be assessed in both legs and in both arms. For all blood pressure assessments, the blood pressure cuff will be manually inflated to a supra-systolic pressure. During slow manual cuff deflation, a Doppler ultrasound (non-invasive) will be used to listen for the first Korotkoff sound, which is the systolic blood pressure. Using this procedure, the systolic blood pressure will be quantified for both the ipsilateral dorsalis pedis and posterior tibial arteries for both legs. Furthermore, systolic blood pressure will be assessed in the brachial arteries of both arms. ABI will be quantified as the ratio of the higher systolic blood pressure in the legs divided by the higher systolic blood pressure in the arms.

3) 6-minute walking test: After the assessments of ABI and PAT, subjects will participate in a 6-min walking test to objectively quantify exercise capacity. Two cones will be separated by 30 m on a straight and flat walkway. Subjects will be instructed to walk back and forth between the cones as fast as they can for 6-min to achieve the farthest distance that they can. Subjects will be allowed to rest during the test, but the stopwatch time will not be stopped. All components of the test will be explained clearly prior to performing the test. Comprehension of the objectives of the test will be confirmed prior to initiating the test. Prior to performing the 6-min walking test, blood pressure, heart rate, and the rating of perceived exertion (RPE) will be recorded in the seated position. Furthermore, blood pressure, heart rate, and RPE will be recorded with the subject in the seated position immediately after exercise and every 5-min thereafter until the pre-exercise heart rate and blood pressure are re-established (w/in +/-5 beats and +/-5 mmHg) in alignment with American College of Sports Medicine guidelines.

The study duration is expected to be \~2.5 hrs, and there will be no follow-up.

02

Conditions studied

  • Peripheral Artery Disease (PAD)

Keywords

  • pulse arrival time
  • atherosclerosis
  • peripheral artery disease
  • portable peripheral artery disease detection
03

In context

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

This study's planned enrollment of 60 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

University of Nebraska is the lead sponsor of 496 studies on the registry; 67 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 53 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. be able to provide written
  2. be 19 years of age or older
  3. having or not having a diagnosis of peripheral artery disease

Exclusion criteria

Exclusion Criteria:

  1. having a current or pervious aortic aneurysm with or without previous intervention
  2. having previous revascularization surgeries (open or endovascular) of the legs or aorta
  3. having walking impairments independent of lower-limb ischemia (e.g., musculoskeletal injury)
  4. having gangrene or ulcers of the toes/feet
  5. being currently pregnant or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Laboratory Visit #1

    During the first and only laboratory visit, subjects will be tested 1) with the experimental device, 2) an ankle-brachial index will be performed, and 3) a 6-min walking test will be performed.

    Device: Segmental pulse arrival time assessment

Interventions

  • DeviceSegmental pulse arrival time assessment

    A proprietary device has been developed to obtain segmental pulse arrival times in the arms and legs. Using this information, the propagation time of the pulse is being investigated as a biomarker to detect the presence of lower-extremity atherosclerosis. Furthermore, the impacts of aging on the biomarker will be assessed.

06

What researchers measure

Primary outcomes

  1. Segmental pulse arrival times

    Pulse arrival time will be assessed in both arms and legs with the investigational device

    Time frame: Day 1

  2. Ankle-brachial index

    Segmental blood pressures in the arms and ankles will be assessed as an index of the presence and/or severity of lower-extremity atherosclerosis. The ankle-brachial index is the standard screening assessment for peripheral artery disease in the lower-extremities.

    Time frame: Day 1

  3. 6-min walking distance

    The 6-min walking test is a standard assessment of mobility in older adults and in patients with peripheral artery disease. The 6-min walking test will be performed to quantify the level of walking impairment in patients with peripheral artery disease.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • University of Nebraska at Omaha Health Science Collaborative
    Omaha, Nebraska 68182, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified IPD will be shared upon request to journals for the purpose of publication. Specific IPD will include the primary outcome measures of this study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 22 months after the start.

Of 260 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 22 months is below that.

Counting every sponsor, half of 385 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2025
First posted
Nov 10, 2025
StartActual
Feb 5, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07226193
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Feb 5, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Cody P Anderson, PhD
Contact
codypanderson@unomaha.edu
402-554-2876

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion